This study aimed to develop a comprehensive predictive model that incorporates EBV-DNA, IgA antibodies, smoking history, family history of NPC, and emerging electrochemical screening techniques to enhance early NPC detection and support clinical decision making (27). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.